News

The companies plan to initiate a Phase III program evaluating the efficacy and safety of VEGF Trap-Eye in the treatment of central retinal vein occlusion (CRVO) in the

Austrian biotechnology company ProtAffin has completed a $18.4m series B financing round. The equity financing was co-led by Atlas Venture and SR One, the corporate venture fund of

For the first quarter of 2009, Hospira reported diluted earnings per share of $1.03, an increase of 151.2%, compared to $0.41 for the first quarter of 2008. The

The company reported total revenues of $691.5 million for the quarter ended March 31, 2009, a decrease of 5.3%, compared to $730.5 million for the quarter ended March

Dendreon, a biotechnology company, has reported promising preclinical data demonstrating the potential of D-3263, the company’s orally bioavailable small molecule, which targets TRPM8, to treat benign prostatic hyperplasia.

For the first quarter of 2009, GAAP income from operations was $5.2 million, compared to $4.4 million in the first quarter of 2008. The company reported total revenues

The net income for the first quarter of 2009 is due to the recognition of non-cash deferred revenue and a decrease in total operating expenses, said Dynavax. The

For the first quarter of 2009, Bristol-Myers Squibb reported diluted earnings per share of $0.32, a decrease of 3%, compared to $0.33 for the same period of 2008.

VaxInnate, a biotechnology company, has reported positive results from the Phase I study of VAX125, the company’s investigational hemagglutinin-flagellin flu vaccine. The flu vaccine was found to be